Loading…
Hosted by The Lancet Haematology · 🇺🇰 uk · EN-UK · 67 episodes
Established thought leaders with verified media credentials.
The Lancet Haematology launched in Autumn 2014, joining the growing collection of Lancet specialty journals. As an exclusively online journal, this new monthly title is dedicated to publishing original research that advocates change in, or illuminates, haematological clinical practice.
The Lancet Haematology hosts Listen to The Lancet Haematology, a science show with 67 episodes published.
Dr Erica Kaye and Dr Dylan Graetz join us to discuss the importance of qualitative research and how the whole research ecosystem can incorporate and support this type of research to help set the right research questions,
The Lancet Haematology share their thoughts and reflect on their experiences at the European Hematology Association, International Conference on Malignant Lymphoma, and International Society on Thrombosis and Haemostasis
With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Hae
Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor r
Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma.
Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for pr
Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukae
Professor Isabelle Mahé joins us to discuss the results of a post-hoc analysis of the API-CAT trial identifying predictors associated with clinically relevant bleeding during extended anticoagulation for cancer-associate
Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025.
Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on classic
Dr. Ruben Mesa joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocy
Authors join us to discuss their recent Series on advances in genomic techniques that have transformed the diagnosis, prognosis, and targeted treatment of mature T-cell and natural killer-cell lymphoma.
Paolo Strati joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractor
Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on ea
Dr Romy Pothof and Prof Joanne Verweij join us to discuss their development of an international consensus on the diagnosis and treatment of fetal and neonatal alloimmune thrombocytopenia.
Prof Helene Schoemans, Elke Stienissen, and Kathy Goris join us to discuss the importance of consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe.
Dr Dawn Swan joins us to discuss current knowledge and future perspectives on the possible association between air pollution and venous thromboembolism.
Dr Leslie Skeith joins us to discuss the PARTUM pilot trial, comparing low-dose aspirin versus placebo in postpartum venous thromboembolism.
Dr Neema Mayor and Dr Caitlin Farrow from the Anthony Nolan Research Institute join us to discuss the findings of their study on the impact of patient ethnicity on haematopoietic cell transplantation outcomes in the Unit
In a special 10 year anniversary podcast, Lan-Lan Smith, Yaiza del Pozo Martin, and Emma Cookson, the editorial team behind The Lancet Haematology, reflect on the last decade and give some insights into the editorial pro
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Listen to The Lancet Haematology has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Listen to The Lancet Haematology is hosted by The Lancet Haematology. The show is categorised under science (medicine) and has published 67 episodes.
Listen to The Lancet Haematology has published 67 episodes.
Listen to The Lancet Haematology regularly covers science, medicine, health. It sits in the science category, with a medicine focus.
Listen to The Lancet Haematology is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Listen to The Lancet Haematology hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Listen to The Lancet Haematology average 21 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Listen to The Lancet Haematology's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 7 days ago.